Skip to content
HowShorted

NRX Pharmaceuticals, Inc. short interest in 2022

In 2022, NRX Pharmaceuticals, Inc.'s disclosed short interest ran from 2.61% of shares outstanding on 14 Jan 2022 to 2.09% on 30 Dec 2022, a change of -0.52 percentage points. The year's high was 5.49% on 14 Apr 2022 and its low 1.87% on 31 Oct 2022, averaging 2.99% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 10.85 days on 14 Oct 2022. Full history: NRX Pharmaceuticals, Inc..

Cite this page
Plain
Wikipedia
BibTeX

By year: 2021 · 2022 · 2023 · 2024 · 2025 · 2026

Aggregate net short position time series for NRX Pharmaceuticals, Inc. in 2022

2022 in figures

Start of year
2.61% (14 Jan 2022)
End of year
2.09% (30 Dec 2022)
Change
-0.52 pp
High
5.49% (14 Apr 2022)
Low
1.87% (31 Oct 2022)
Average
2.99%
Highest days to cover
10.85 (14 Oct 2022)
SEC filings marked
5

Every report in 2022

NRX Pharmaceuticals, Inc. short interest in 2022
SettlementShort interestDays to coverFilings since previous
14 Jan 20222.61%1.36
31 Jan 20223.60%2.42
15 Feb 20224.16%2.26
28 Feb 20224.81%4.85
15 Mar 20224.97%3.59
31 Mar 20225.31%4.5910-K filed
14 Apr 20225.49%8.15
29 Apr 20223.87%5.47
13 May 20222.89%3.82
31 May 20222.98%1.0010-Q filed
15 Jun 20222.33%1.00
30 Jun 20222.51%3.76
15 Jul 20222.29%3.60
29 Jul 20222.37%1.00
15 Aug 20222.36%1.0010-Q filed
31 Aug 20222.38%2.55
15 Sep 20221.92%4.46
30 Sep 20222.41%6.04
14 Oct 20222.17%10.85
31 Oct 20221.87%7.59
15 Nov 20221.94%4.5210-Q filed, results (8-K)
30 Nov 20222.18%1.93
15 Dec 20222.24%4.43
30 Dec 20222.09%4.88

See also: NRX Pharmaceuticals, Inc.'s full history · most shorted US stocks of 2022 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.